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Abstract
Background: Serum alanine aminotransferase (ALT) is a marker of liver injury. The 2005 American Gastroenterology
Association Future Trends Committee report states that serum ALT levels remain constant with age. This study examines the
association between serum ALT and age in a community-dwelling cohort in the United States.
Methods: A cross-sectional study of 2,364 (54% female) participants aged 30–93 years from the Rancho Bernardo Study
cohort who attended a research clinic visit in 1984–87. Demographic, metabolic co-variates, ALT, bilirubin, gamma glutamyl
transferase (GGT), albumin, and adiposity signaling biomarkers (leptin, IL-6, adiponectin, ghrelin) were measured.
Participants were divided into four-groups based upon age quartile, and multivariable-adjusted least squares of means
(LSM) were examined (p for trend ,0.05).
Results: ALT decreased with increasing age, with mean ALT levels (IU/L) of 23, 21, 20, and 17 for those between quartile
ages 30–62, 63–71, 72–77, and 78–93 years (p,0.0001). Trends of decreasing LSM ALT with age and the decreasing
prevalence of categorically defined elevated serum ALT with age remained robust after adjusting for sex, alcohol use,
metabolic syndrome components, and biomarkers of adiposity (p-value ,0.0001), and was not materially changed after
adjusting for bilirubin, GGT, and albumin.
Conclusions: ALT levels decrease with age in both men and women independent of metabolic syndrome components,
adiposity signaling biomarkers, and other commonly used liver function tests. Further studies are needed to understand the
mechanisms responsible for a decline in ALT with age, and to establish the optimal cut-point of normal ALT in the elderly.
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Introduction
Serum alanine aminotransferase (ALT) level is frequently used
as a surrogate marker for hepatocyte injury. Normal ranges vary
according to the commercial kit used, but have historically been
set at around 40 IU/L. This value was based on population studies
conducted before the availability of blood tests for hepatitis C and
before the widespread recognition of nonalcoholic fatty liver
disease (NAFLD). Recently, some have suggested that not only
should the upper limits of normal for ALT be lowered, but that
limits should differ based on sex as well [1], [2], [3]. Since then,
many other factors have been implicated in differing ALT levels.
Most of these factors are features related to the metabolic
syndrome, including body mass index, waist-hip ratio, dyslipide-
mia, and glucose intolerance [4–13]. The relationship between
ALT and age, however, remains somewhat ambiguous.
The 2005 American Gastroenterology Association Future
Trends Committee report regarding the effects of aging on future
trends in gastroenterology states that there is no effect of age on
conventional liver function tests, including serum ALT [14]. A
study of serum ALT concentrations in healthy Iranian blood
donors also concluded that ALT did not correlate with age [15].
However, a few studies published since that time have reported
that the prevalence of elevated (abnormal) ALT decreases with age
[4], [6], [7], [8], [10], [11]. Some have found this association to be
true in men, but not in women [3], [5], [16]. Most of these studies
were performed using retrospective chart reviews of patients who
had laboratory tests, including serum ALT, for medical reasons, in
self-selected populations (such as blood donors), or in Asian
populations, whose liver function may differ compared to Western
populations. A recent study of community dwelling elderly men
(over age 70) suggested that ALT may be a novel biomarker of
aging, with levels decreasing with rising age, and low levels
associating with frailty and reduced survival [17].
The largest United States population-based study of ALT levels
is from the National Health and Nutrition Examination Survey
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.40 U/L in men and .31 U/L in women) and the 1999–2002
[7] (elevated ALT defined as .43 U/L in both men and women)
cross-sectional reports, older age was associated with a decreased
prevalence of elevated ALT levels, but the conventionally higher
ALT cutoff values were used in these analyses. It is therefore
uncertain whether age was associated with serum ALT concen-
trations within the normal range, and whether the associations
between age and the prevalence of categorically defined elevated
ALT would have remained had lower ALT thresholds been
applied. The latter question was answered by Ruhl and Everhart
[4], who examined data from the NHANES 1988–1994 survey
using both the traditionally higher ALT cutoff threshold (.43 IU/
L) as well as lower thresholds ($30 IU/L for men and $19 IU/L
for women). They found that in univariate analysis, younger age
was associated with abnormally elevated ALT activity.
Thus, there seems to be an association between younger age
and increased prevalence of elevated ALT. However, it is still
unclear whether serum ALT levels within the normal range
decline with age, and if so, whether this decline is related to
changes in body mass, central adiposity, or other plausible
covariates. Additionally, it is unclear whether the threshold of
extreme values of ALT (e.g. 95
th percentile of ALT range for a
particular age group) also varies with age.
To the best of our knowledge, this paper is the first to examine
the association between serum ALT level as a continuous variable
and age, including ALT levels that are within normal range as well
as those that are elevated, in a well-characterized [12], [18], [19],
healthy, community-dwelling cohort of older men and women
residing in Southern California. We also determined whether any
age-related changes in serum ALT were explained by metabolic
syndrome components, adiposity-related biomarkers including
leptin, adiponectin, ghrelin and interleukin-6 (IL-6), or other
markers of hepatic function (bilirubin, albumin, gamma glutamyl
transferase [GGT]).
Methods
Study Cohort and Setting
This cross-sectional study is based on data from participants of
the Rancho Bernardo Study (RBS). The RBS cohort was
established in 1972, when 82% of residents of a geographically
defined suburban Southern California community were recruited
to a study of heart disease risk factors. The details of the cohort,
selection criteria, and purpose of the RBS have been published
elsewhere [18], [19]. The current study cohort was derived from
2480 residents who attended the research clinic between 1984 and
1987, approximately 80% of the surviving, local, community-
dwelling adults. Of these, 2364 participants were aged 30 years or
older and had available ALT data and were included in the
current analysis [12]. The RBS cohort is almost entirely Caucasian
of European ancestry, most with at least some college education,
and largely white-collar workers. All participants gave written
informed consent; the study was approved by the institutional
review board of the University of California, San Diego.
Clinical and Laboratory Assessment
A trained interviewer gathered information regarding medical
history and current medication use. Weight was obtained with
participants wearing light clothing and no shoes. Height, waist and
hip circumference, and systolic blood pressure were obtained in
clinic by trained investigators. Blood pressure was obtained from
two morning readings with the resting participant in the seated
position, using a regularly calibrated mercury sphygmomanome-
ter, according to the Hypertension Detection and Follow-up
Program protocol [20]. Alcohol use, in terms of amount, type, and
frequency, was self-reported. One alcoholic drink was defined as
10 g of alcohol. Alcohol use was indirectly validated by showing a
similar quantitative response to a nutritionist interviewer who
obtained alcohol intake as part of a separate food-frequency
questionnaire. Fasting venous blood was analyzed in a clinical
laboratory. ALT, bilirubin, GGT and albumin were measured
using a single assay by spectrophotometry on fresh samples.
Fasting serum samples were obtained during the research visit;
they were measured in all participants using the same assay and
under identical testing conditions at a UCSD clinical laboratory.
Total cholesterol, high-density lipoprotein (HDL) cholesterol, and
triglyceride levels were measured using enzymatic methods in a
Lipid Research Clinic-certified laboratory. Plasma glucose was
measured in a hospital laboratory using the glucose-oxidase
method. Diabetes was defined as a fasting glucose of $126 mg/dL
($7 mmol/L) or treatment with either insulin or an oral
hypoglycemic medication. Adipocytokine studies were performed
on samples stored at 270uC. IL6 was measured using an enzyme-
linked immunosorption assay (Quantikine HS, R&D Systems,
Minneapolis, MN) on previously unthawed samples in 2000.
Adiponectin, ghrelin, and leptin were measured in 2004 (samples
thawed for a second time) by radioimmunoassay (Linco Diagnos-
tics Laboratory, St. Louis, MO) as previously reported [21], [22].
The laboratory reports that there is no loss of assay sensitivity or
adipocytokine degradation with two freeze-thaw cycles, and levels
in our study are similar to those reported in the literature using the
same assays [23], [24], [25], [26]. Adequate blood samples for
serum leptin, IL-6, adiponectin, and ghrelin concentrations were
available for 1565, 1843, 1572, and 1556 of 2364 individuals,
respectively.
Elevated ALT was defined, a priori, as an ALT $30 IU/L for
men and $19 IU/L for women as proposed by Prati et al [2].
Statistical Analysis
The cohort was divided into the following four groups based
upon the age quartiles: 30–62, 63–71, 72–77, and 78–93 years.
Descriptive statistics were described in participants classified into
these quartile age groups. Serum ALT, bilirubin, GGT, albumin,
triglycerides, IL-6, leptin, adiponectin, and ghrelin were log
transformed for statistical analyses to fulfill conditions of
normality. Least squares means were used to examine the trends
in serum ALT, bilirubin, GGT, and albumin across the four age
groups and p-value for trend was examined. Multivariate
hierarchical models were used to examine the relationship
between ALT and age that included: 1. Un-adjusted, 2. Multiply
adjusted for sex, BMI, systolic blood pressure, alcohol use, waist-
hip ratio, diabetes, fasting glucose, total cholesterol-HDL choles-
trol ratio, triglycerides, IL-6, leptin, adiponectin, and ghrelin, and
3. Multiply adjusted with the above plus commonly used liver
function tests (bilirubin, GGT, and albumin). Additionally, we
conducted multivariate-adjusted models to examine the associa-
tion between age and prevalence of categorically defined elevated
serum ALT across these four age groups, and p-value for trend
was examined. Statistical analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC). A two-tailed p-value of less
than 0.05 was considered statistically significant.
Results
Population Characteristics
Cohort characteristics of the 1044 men (44.2%) and 1320
women (55.8%) are shown in table 1. The mean 6 standard
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Average (mean 6 SD) BMI was 24.963.7 kg/m
2 and average
waist-hip ratio was 0.860.1. 36.8% reported no alcohol use, 22%
reported ,1 drink/day, 26.8% reported 1–2 drinks/day, and
14.5% reported .2d r i n k s / d a y .T h em e a n6 SD systolic blood
pressure was 139622 mmHg. The mean 6 SD for total and
HDL cholesterol was 220640 mg/dL and 62619 mg/dL,
respectively. 14.3% of the cohort had diabetes. Geometric mean
(95% CI) concentrations for leptin, IL-6, adiponectin, and
ghrelin were 8.6 mg/L (8.2–8.9 mg/L), 2.4 pg/ml (2.3–2.5
pg/ml), 11.7 mg/ml (11.3–12.0 mg/ml), and 1345.3 pg/ml
(1317.9–1373.2 pg/ml), respectively. Geometric means (95%
CI) for bilirubin, GGT, and albumin were 0.5 mg/dl (0.5–
0.5 mg/dl), 9.8 IU/L (9.5–10.1 IU/L), and 4.3 g/dl (4.3–4.3 g/
dl), respectively.
Analysis of each of these variables by age showed a significant
age trend for BMI, waist-hip ratio (marker of central adiposity),
alcohol use, systolic blood pressure, elevated cholesterol, preva-
lence of diabetes, leptin, adiponectin, IL-6, bilirubin, and albumin
with increasing age. BMI and albumin decreased with increasing
age, while waist-hip ratio, systolic blood pressure, prevalence of
diabetes, adiponectin, IL-6, and bilirubin increased with age.
GGT did not show a significant trend with age.
ALT Trends
Serum ALT Declines With Age. For all participants
combined, ALT was highest in the youngest (30–62) age group,
with a mean 6 SD ALT of 23615 IU/L for that group.
Subsequently, ALT decreased with increasing age, from
21614 IU/L for those aged 63–71 years, to 20621 IU/L for
Table 1. Cohort Characteristics.
Total
Age Quartile 1
(30–62 years)
Age Quartile 2
(63–71 years)
Age Quartile 3
(72–77 years)
Age Quartile 4
(78–93 years) P-trend
No of individuals 2364 597 574 589 604
Women (%) 55.8 57.0 57.8 58.2 50.5 .0357
BMI (kg/m
2) (Mean6SD) 24.963.7 25.564.0 25.263.7 24.763.6 24.463.4 ,.0001
Waist-hip ratio (Mean6SD) 0.860.1 0.860.1 0.860.1 0.860.1 0.860.1 ,.0001
Alcohol use (%) ,.0001
None 36.8 36.5 34.8 32.1 43.4
,1 drink/day 22.0 25.0 18.8 22.6 21.4
1–2 drinks/day 26.8 22.5 27.0 31.4 26.5
.2 drinks/day 14.5 16.1 19.3 13.9 8.8
Systolic blood pressure (mmHg)
(Mean6SD)
138.9621.9 124.0618.4 136.3618.7 144.5619.2 150.7621.5 ,.0001
Total cholesterol (mg/dl)
(Mean6SD)
219.9640.0 218.7636.6 228.1641.5 219.6640.5 213.5639.9 .0009
HDL cholesterol (mg/dl)
(Mean6SD)
61.7618.7 60.9618.2 62.3619.9 62.9620.1 60.9616.7 .8538
Total/HDL cholesterol ratio
(Mean6SD)
3.961.3 3.961.3 4.061.3 3.861.3 3.861.2 .0120
{ Triglycerides (mg/dl) (95% CI) 102.0 (99.8–104.3) 100.2 (95.9–104.7) 111.3 (106.4–116.4) 101.7 (97.3–106.3) 95.8 (91.7–100.1) .0245
Diabetes (%) 14.3 7.4 12.5 17.7 19.7 ,.0001
{* Leptin (mg/L) (95% CI) 8.5 (8.2–8.9) 7.1 (6.6–7.8) 9.2 (8.5–9.9) 9.1 (8.5–9.8) 8.6 (8.0–9.2) .0015
{* Adiponectin (mg/ml) (95% CI) 11.7 (11.3–12.0) 8.6 (8.1–9.2) 10.7 (10.1–11.3) 12.7 (12.1–13.4) 14.0 (13.3–14.7) ,.0001
{* Ghrelin (pg/ml) (95% CI) 1345.2
(1317.9–1373.2)
1333.3
(1272.9–1396.5)
1303.7
(1249.5–1360.2)
1367.2
(1313.8–1422.7)
1366.8
(1316.6–1418.9)
.2028
{* IL-6 (pg/ml) (95% CI) 2.4 (2.3–2.5) 1.8 (1.7–1.9) 2.3 (2.2–2.5) 2.8 (2.6–3.0) 3.1 (2.9–3.3) ,.0001
ALT (IU/L) (Mean 6 SD) 20.2615.6 22.8614.7 20.8613.6 19.8621.2 17.3610.2 ,.0001
Men 22.0619.1 26.5614.9 22.7615.6 21.4630.5 17.969.1 ,.0001
Women 18.8611.9 20.1614.0 19.5611.8 18.6610.2 16.8611.1 .0003
{ALT (IU/L) (95% CI) 17.4 (17.1–17.8) 19.6 (18.9–20.4) 18.1 (17.4–18.9) 16.9 (16.2–17.6) 15.4 (14.8–16.1) ,.0001
Elevated ALT (%) 28.0 35.3 31.0 28.4 17.4 ,.0001
Men ($30 IU/L) 15.3 28.0 15.3 11.4 7.7 ,.0001
Women ($19 IU/L) 38.0 40.9 42.5 40.5 26.9 .0004
{ GGT (IU/L) (95% CI) 9.8 (9.5–10.1) 9.7 (9.1–10.2) 10.5 (9.9–11.1) 9.9 (9.3–10.4) 9.3 (8.8–9.9) .2000
{ Bilirubin (mg/dl) (95% CI) 0.5 (0.5–0.5) 0.4 (0.4–0.4) 0.4 (0.5–0.5) 0.5 (0.5–0.5) 0.6 (0.5–0.6) ,.0001
Albumin (g/dl) (95% CI) 4.3 (4.3–4.3) 4.4 (4.4–4.5) 4.4 (4.4–4.4) 4.2 (4.2–4.3) 4.1 (4.1–4.2) ,.0001
{Geometric means.
*Smaller sample sizes: Leptin (N=1565), Adiponectin (N=1572), Gherlin (N=1556), IL-6 (N=1843).
CI = confidence interval; SD = standard deviation.
doi:10.1371/journal.pone.0014254.t001
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years.
In sex-specific analyses, ALT decreased with increasing age for
both men and women. In men, the highest ALT of
26.5614.9 IU/L was observed in the 30–62 year age group,
subsequently dropping to 22.7615.6 IU/L, 21.4630.5 IU/L, and
17.969.1 IU/L for each of the progressive age subcategories
(Figure 1). ALT in women started at 20.1614.0 IU/L in the 30–
62 year age group, then gradually dropped thereafter to
19.5611.8 IU/L, 18.6610.2 IU/L, and 16.8611.1 IU/L for
the subsequent age subcategories (Figure 2). The 95th percentile
cutoff value for ALT also decreased with age, suggesting that
extreme ALT values for each respective age-category declined as
well (Figures 1 and 2).
Least Squares of Mean of ALT and Age. Results remained
consistent when least squares means of serum ALT were analyzed
across all four age groups, using p-value for trend (p-value
,0.0001). After multivariable adjustment for sex, BMI, systolic
blood pressure, alcohol use, waist-hip ratio, diabetes, fasting
glucose, total cholesterol to HDL radio, triglycerides, IL-6,
adiponectin, and ghrelin, the trend of decreasing least squares
means of ALT with age remained consistent and statistically
significant (p,0.0001). Addition of bilirubin, GGT, and albumin
to the multivariable model did not significantly change the
statistical association (p,0.0001) (Table 2).
Elevated ALT Declines With Age. Using elevated ALT
cutoff values of $30 IU/L for men and $19 IU/L for women as
proposed by Prati et al. [2], the prevalence of abnormally elevated
ALT was highest in the 30–63 year age group at 35.3%, then
subsequently gradually declined to 31%, 28.4%, and 17.4% for
each progressive age subcategory (p,0.0001) (Figure 3).
Similarly, after multivariate adjustment of prevalence of
elevated ALT for sex, BMI, systolic blood pressure, alcohol use,
waist-hip ratio, diabetes, fasting glucose, total cholesterol to HDL
ratio, triglycerides, leptin, IL-6, adiponectin, ghrelin, bilirubin,
GGT, and albumin, results remained statistically significant and
showed a consistent downward trend of prevalence of elevated
ALT with increasing age (p=0.0001, Figure 3).
Trends in Bilirubin, GGT, and Albumin
In unadjusted analyses, rising bilirubin (from 0.4 mg/dL in the
youngest quartile to 0.6 mg/dL in the oldest quartile) and falling
albumin (from 4.4 g/dL in the youngest quartile to 4.1 g/dL in
the oldest quartile) were associated with increasing age, while
GGT had no association. After multivariable adjustments for sex,
BMI, systolic blood pressure, alcohol use, waist-hip ratio, diabetes,
fasting glucose, total-HDL ratio, triglycerides, and adiposity
biomarkers (leptin, adiponectin, ghrelin, IL-6), trends in rising
bilirubin and falling GGT and albumin levels with increasing age
remained significant with p-values for trend ,0.05. Bilirubin
increased from 0.4 mg/dL in the youngest group to 0.6 mg/dL in
the oldest group, GGT decreased from 11.7 IU/L in the youngest
group to 9.9 IU/L in the oldest group, and albumin decreased
from 4.5 g/dL to 4.2 g/dL in those groups.
Discussion
Principal Findings
In this population-based, community-dwelling cohort of older
men and women residing in Southern California, ALT levels
decreased with age for both sexes. Even after multivariate
adjustments for factors previously found in other studies to be
associated with differing ALT levels (sex [2], [4], [7], [8], [11];
alcohol use [7]; components of the metabolic syndrome [4–11]:
BMI, waist-hip ratio, diabetes, fasting glucose, total cholesterol to
HDL ratio, triglycerides), for surrogate markers of adiposity (leptin
[4], IL-6 [27], [28], adiponectin [29], [30], ghrelin [31], [32]), and
for other markers of liver function (bilirubin, GGT, albumin), the
association of rising age with decreasing ALT remained significant
(p,0.0001, Table 2). Correspondingly, the extreme values of ALT
(95
thpercentile cutoffpointsforupperlimitofALT,Figures1and2)
as well as the prevalence of elevated ALT (p,0.0001,Figure 3) both
decreased with rising age as well. These data suggest that age is an
independent and robust predictor of serum ALT within normal
range as well as of elevated serum ALT, and this association is
independent of adiposity, known metabolic correlates of ALT, and
possibly liver function. We also found that serum albumin declines
with increase in age, perhaps related to a decline in muscle mass.
Serum GGT did not decrease with increase in age in unadjusted
analyses but after adjustment for metabolic correlates it also showed
a decrease with age. Bilirubin increased with increasing age.
Speculations on Causes and Implications for Future
Research
We initially hypothesized that perhaps this trend may be related
to decreasing adiposity with advancing age, leading to a decreased
Figure 1. Effect of Age on ALT Values in Men (Mean and 95%
Confidence Interval). In men, mean ALT (bars) and 95th percentile
cutoff ranges (extension lines) both decrease with rising age.
doi:10.1371/journal.pone.0014254.g001
Figure 2. Effect of Age on ALT Values in Women (Mean and
95% Confidence Interval). In women, mean ALT (bars) and 95th
percentile cutoff ranges (extension lines) both decrease with rising age.
doi:10.1371/journal.pone.0014254.g002
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cohort characteristics, while BMI decreased with age, waist-hip
ratio, and IL-6 increased with age, suggesting that central obesity
(a component of the metabolic syndrome) increased with age. This
finding is somewhat contrary to our hypothesis. These age-related
anthropometric and cytokine changes are complex and do not
account for the decline in serum ALT. Furthermore, age retained
a clinically and statistically significant association with ALT
despite multivariable adjustment for these metabolic characteris-
tics and biomarkers.
Another potential explanation is that a decrease in ALT signifies
a true decrease in prevalence of liver disease. While the prevalence
of significant alcohol use in our cohort did decline with older age,
peak consumption occurred at ages after ALT levels started to fall.
Furthermore, the trend of decreasing ALT with age persisted after
adjusting for alcohol intake, suggesting that alcohol consumption
alone does not account for the decrease in ALT with age.
Information regarding viral hepatitis was not available in our
study cohort, therefore these participants could not be excluded.
Theoretically, a higher burden of chronic viral hepatitis in younger
individuals could lead to higher ALT levels in this age group.
However, data from NHANES suggests that this is not the case.
The prevalence of hepatitis B infection was found to increase with
increasing age among Caucasians [35]. While hepatitis C
prevalence decreased among Caucasians aged 50 and older, the
prevalence rate was only 0.7% [36], therefore any effects of
decreasing hepatitis C prevalence would be offset by increasing
hepatitis B prevalence, making the overall contribution of viral
hepatitis to population ALT trends minimal.
Decreased prevalence of liver disease may also reflect selective
survival bias, whereby those with high levels are more likely to
have died. A study of 8043 construction workers by Arndt et al.
[33] found that elevated liver enzymes predicted a significantly
increased risk of all-cause mortality. Adams et al. [34] found that
mortality was significantly higher in community-dwelling patients
with NAFLD compared to the general population. Due to the
cross-sectional nature of this study, we cannot exclude this
possibility. Alternatively there is a yet unidentified lifestyle or
clinical factor which confers protection to liver disease as one ages.
Another possibility is that decreasing ALT signifies a decrease in
the mass or function of the normal liver. This is plausible given
that albumin levels decreased with age and bilirubin levels
Table 2. Least Square Means of ALT by Age.
ALT
Age Quartile 1
(30–62 years)
Age Quartile 2
(63–71 years)
Age Quartile 3
(72–77 years)
Age Quartile 4
(78–93 years) P-trend
Unadjusted 19.6 18.1 16.9 15.4 ,.0001
{*Multivariate adjusted 21.5 18.5 17.4 15.9 ,.0001
{* Multivariate adjusted with addition of GGT,
bilirubin, and albumin
20.9 18.3 17.5 16.4 ,.0001
{Multi-variate adjustment for sex, BMI, systolic blood pressure, alcohol use, waist-hip ratio, diabetes, fasting glucose, total-HDL ratio, triglycerides, leptin, adiponectin,
ghrelin, and IL-6.
*Smaller sample sizes: Leptin (N=1565), Adiponectin (N=1572), Gherlin (N=1556), IL-6 (N=1843).
Geometric means used for ALT, leptin, adiponectin, ghrelin, GGT, and bilirubin.
doi:10.1371/journal.pone.0014254.t002
Figure 3. Prevalence of Elevated ALT by Age. The trend of decreasing prevalence of elevated ALT with rising age persists in unadjusted analysis,
after adjustment for sex, BMI, systolic blood pressure, alcohol use, waist-hip ratio, diabetes, fasting glucose, total-HDL ratio, triglycerides, adiposity
biomarkers (leptin, adiponectin, ghrelin, IL-6), and after adjustments for the above plus bilirubin, GGT, and albumin.
doi:10.1371/journal.pone.0014254.g003
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tion regarding functional status of the liver and are considered to
be true liver function tests. Studies comparing young and old livers
in rats showed that older livers have slower and weaker
regenerative capacity, a decrease in homeostatic capacity, and a
lower inflammatory response rate [37]. In rat models of liver
transplantation, aged livers showed a reduced organ weight,
increased hepatocyte degeneration, and increased fibrosis [38],
[39]. Similarly in humans, older livers show a progressive decrease
in size and blood flow, and changes related to the accumulation of
oxidative stress [40], [41], [42]. In studies by Elinav et al. [43] and
Le Couteur et al. [17], an ALT value below the median was a
strong and independent predictor of mortality in community-
dwelling elderly men. In our study, modest decreases in albumin
and GGT and increases in bilirubin were observed with increasing
age after adjustments for sex, alcohol use, metabolic syndrome
traits, and surrogate markers of adiposity, suggesting that a
decrease in liver function may indeed be present. However,
bilirubin, GGT, and albumin are also complex biomarkers and
may not solely reflect hepatic function. Furthermore, the trend of
decreasing ALT with increasing age remained significant after
adjusting for bilirubin, GGT, and albumin.
An additional possibility is that the prevalence of liver disease is
the same or perhaps higher in elderly subjects, but the ALT is not
a reliable marker of hepatocyte injury. In our study, age was
associated with increasing central obesity, systolic blood pressure,
and prevalence of diabetes, all factors associated with the
metabolic syndrome and NAFLD. Although ALT is frequently
used in the evaluation of NAFLD, it has been shown to correlate
poorly with liver histology in subjects of all ages [44], [45]. This
lack of correlation with ALT levels in the elderly could be
increased in part due to a decrease in the inflammatory response of
the older liver, as discussed above. Others have suggested that
elderly subjects with NAFLD tend to have more fibrosis on liver
biopsy compared to younger subjects who tend to have more
steatosis or steatohepatitis. Frith et al. [46] examined 351
consecutive patients with biopsy-proven NAFLD, and found that
age .60 was significantly associated with fibrosis. Similar results
were found by Angulo et al. [47] and Miyaaki et al. [48].
Finally, ALT was a marker of age independent of other liver
function tests, including bilirubin, GGT, and albumin. Others
have also speculated that ALT may be a novel biomarker of aging
[17].
Strengths and Limitations
The strengths of this study include the use of a population-
based, well-characterized cohort of healthy, community-dwelling
elderly men and women. Analysis of data obtained from a research
clinic visit 12–15 years after the initial establishment of the cohort
allowed the unique opportunity to study an older group of
individuals. One potential limitation of our study is that
information regarding chronic liver diseases, such as viral hepatitis,
autoimmune hepatitis, or metabolic liver diseases, was not
available, thus we were not able to exclude these individuals.
However, these conditions are not so common that they would be
expected to influence the results. Our study cohort is fairly
uniform (predominantly Caucasian, middle to upper-middle class),
suggesting good internal validity of the findings. However,
generalizability of these findings in other ethnic groups or socio-
economic classes would require further studies in other more
diverse cohorts.
In conclusion, ALT levels were not constant, but decreased with
increasing age for both men and women, independent of
components of the metabolic syndrome, surrogate markers of
adiposity, and other markers of hepatic function. As a conse-
quence, an ALT value which is considered normal for a younger
individual may fall outside of 2 standard deviations for an older
individual. The reasons for these differences and the clinical
implications of decreasing ALT with age remain to be determined.
Future longitudinal studies are needed to confirm our findings and
examine the factors that explain the association between the
decline in serum ALT with rising age.
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